Jens Huober

Research interests

Publications

• Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.23.01994

• Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.017

• Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00694-5

• Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.07.1940

• Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.015

• Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00301-6

• Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.10.471

• Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.05.015

• NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.01842

• A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz158

• Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30111-6

• Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30904-x

• MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.75.6155

• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx308

• Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

  JAMA Oncology · 2017 · https://doi.org/10.1001/jamaoncol.2017.1007

• Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials

  Breast Cancer Research and Treatment · 2015 · https://doi.org/10.1007/s10549-015-3479-z

• Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials

  Breast Cancer Research and Treatment · 2015 · https://doi.org/10.1007/s10549-015-3287-5

• PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2014.55.7876

• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70160-3

• Response-Guided Neoadjuvant Chemotherapy for Breast Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.45.0940

• Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.38.8595

• Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

  The Breast · 2011 · https://doi.org/10.1016/j.breast.2011.07.006

• Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.24.7643

• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

  Breast Cancer Research and Treatment · 2010 · https://doi.org/10.1007/s10549-010-1228-x

• Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

  Clinical Cancer Research · 2010 · https://doi.org/10.1158/1078-0432.ccr-09-2042

• Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

  Annals of Surgical Oncology · 2006 · https://doi.org/10.1245/s10434-006-9058-0

Current projects

No projects listed.